Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial

Beryl A Koblin, Martin Casapia, Cecilia Morgan, Li Qin, Zhixue Maggie Wang, Olivier D Defawe, Lindsey Baden, Paul Goepfert, Georgia D Tomaras, David C Montefiori, M Juliana McElrath, Lilian Saavedra, Chuen-Yen Lau, Barney S Graham, NIAID HIV Vaccine Trials Network, Beryl A Koblin, Martin Casapia, Cecilia Morgan, Li Qin, Zhixue Maggie Wang, Olivier D Defawe, Lindsey Baden, Paul Goepfert, Georgia D Tomaras, David C Montefiori, M Juliana McElrath, Lilian Saavedra, Chuen-Yen Lau, Barney S Graham, NIAID HIV Vaccine Trials Network

Abstract

Background: In the development of HIV vaccines, improving immunogenicity while maintaining safety is critical. Route of administration can be an important factor.

Methodology/principal findings: This multicenter, open-label, randomized trial, HVTN 069, compared routes of administration on safety and immunogenicity of a DNA vaccine prime given intramuscularly at 0, 1 and 2 months and a recombinant replication-defective adenovirus type 5 (rAd5) vaccine boost given at 6 months by intramuscular (IM), intradermal (ID), or subcutaneous (SC) route. Randomization was computer-generated by a central data management center; participants and staff were not blinded to group assignment. The outcomes were vaccine reactogenicity and humoral and cellular immunogenicity. Ninety healthy, HIV-1 uninfected adults in the US and Peru, aged 18-50 were enrolled and randomized. Due to the results of the Step Study, injections with rAd5 vaccine were halted; thus 61 received the booster dose of rAd5 vaccine (IM: 20; ID:21; SC:20). After the rAd5 boost, significant differences by study arm were found in severity of headache, pain and erythema/induration. Immune responses (binding and neutralizing antibodies, IFN-γ ELISpot HIV-specific responses and CD4+ and CD8+ T-cell responses by ICS) at four weeks after the rAd5 booster were not significantly different by administration route of the rAd5 vaccine boost (Binding antibody responses: IM: 66.7%; ID: 70.0%; SC: 77.8%; neutralizing antibody responses: IM: 11.1%; ID: 0.0%; SC 16.7%; ELISpot responses: IM: 46.7%; ID: 35.3%; SC: 44.4%; CD4+ T-cell responses: IM: 29.4%; ID: 20.0%; SC: 35.3%; CD8+ T-cell responses: IM: 29.4%; ID: 16.7%; SC: 50.0%.)

Conclusions/significance: This study was limited by the reduced sample size. The higher frequency of local reactions after ID and SC administration and the lack of sufficient evidence to show that there were any differences in immunogenicity by route of administration do not support changing route of administration for the rAd5 boost.

Trial registration: ClinicalTrials.gov NCT00384787.

Conflict of interest statement

Competing Interests: PG is an Academic Editor for PLoS.

Figures

Figure 1. Study flow diagram.
Figure 1. Study flow diagram.
Figure 2. Anti-Env Binding antibody response by…
Figure 2. Anti-Env Binding antibody response by administration route at 4 weeks post Ad5 boost.
Anti-Env binding antibody levels and % response are shown per route of administration. Positive responses are in red and non-responders in blue.
Figure 3. Interferon-γ ELISpot response to Env,…
Figure 3. Interferon-γ ELISpot response to Env, Gag, Nef, Pol global PTE peptide stimulation by administration route.
(A) At 2 weeks post last DNA prime and (B) 4 weeks post Ad5 boost. The scale indicates spot-forming cells per million peripheral blood mononuclear cells.
Figure 4. Percentage of CD4+ T cells…
Figure 4. Percentage of CD4+ T cells producing interferon γ and/or Interleukine 2 by administration route.
(A) in response to any Env peptides (B) in response to any Gag peptides before (2 weeks post last DNA prime) and after the Ad5 boost (4 weeks post Ad5 boost).
Figure 5. Percentage of CD8+ T cells…
Figure 5. Percentage of CD8+ T cells producing interferon γ and/or Interleukine 2 by administration route.
(A) in response to any Env peptides (B) in response to any Pol peptides before (2 weeks post last DNA prime) and after the Ad5 boost (4 weeks post Ad5 boost).

References

    1. Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature. 2008;455:613–619.
    1. Sell S, Max EE. Immunology, Immunopathology and Immunity. Herndon: ASM Press; 2001. 774
    1. Bos JD. Skin Immune System. Boca Raton: CRC Press; 1997. 719
    1. Norbury CC, Malide D, Gibbs JS, Bennink JR, Yewdell JW. Visualizing priming of virus-specific CD8+ T cells by infected dendritic cells in vivo. Nat Immunol. 2002;3:265–271.
    1. Peachman KK, Rao M, Alving CR. Immunization with DNA through the skin. Methods. 2003;31:232–242.
    1. Jakob T, Udey MC. Epidermal Langerhans cells: from neurons to nature's adjuvants. Adv Dermatol. 1999;14:209–258.
    1. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med. 2004;351:2295–2301.
    1. Belshe RB, Newman FK, Cannon J, Duane C, Treanor J, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med. 2004;351:2286–2294.
    1. Ghabouli MJ, Sabouri AH, Shoeibi N, Bajestan SN, Baradaran H. High seroprotection rate induced by intradermal administration of a recombinant hepatitis B vaccine in young healthy adults: comparison with standard intramuscular vaccination. Eur J Epidemiol. 2004;19:871–875.
    1. Frosner G, Steffen R, Herzog C. Virosomal hepatitis a vaccine: comparing intradermal and subcutaneous with intramuscular administration. J Travel Med. 2009;16:413–419.
    1. Wilck MB, Seaman MS, Baden LR, Walsh SR, Grandpre LE, et al. Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration. J Infect Dis. 2010;201:1361–1370.
    1. Arnou R, Icardi G, De DM, Ambrozaitis A, Kazek MP, et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine. 2009;27:7304–7312.
    1. Pittman PR, Kim-Ahn G, Pifat DY, Coonan K, Gibbs P, et al. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine. 2002;20:1412–1420.
    1. Ruben FL, Froeschle JE, Meschievitz C, Chen K, George J, et al. Choosing a route of administration for quadrivalent meningococcal polysaccharide vaccine: intramuscular versus subcutaneous. Clin Infect Dis. 2001;32:170–172.
    1. Henderson EA, Louie TJ, Ramotar K, Ledgerwood D, Hope KM, et al. Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers. Infect Control Hosp Epidemiol. 2000;21:264–269.
    1. Catanzaro AT, Koup RA, Roederer M, Bailer RT, Enama ME, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis. 2006;194:1638–1649.
    1. Catanzaro AT, Roederer M, Koup RA, Bailer RT, Enama ME, et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine. 2007;25:4085–4092.
    1. Koup RA, Roederer M, Lamoreaux L, Fischer J, Novik L, et al. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One. 2010;5:e9015.
    1. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372:1881–1893.
    1. Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol. 2004;172:6290–6297.
    1. Morgan C, Bailer R, Metch B, Koup R, Paranjape R, et al. International seroprevalence of neutralizing antibodies against adenoviral serotypes 5 and 35. 2005. AIDS Vaccine 2005 Montreal, Canada.
    1. Goepfert PA, Tomaras GD, Horton H, Montefiori D, Ferrari G, et al. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine. 2007;25:510–518.
    1. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol. 2008;82:12449–12463.
    1. Montefiori DC. Evaluating neutralizing antibodies against HIV, SIV and SHIV in luciferase reporter gene assays. In: Coligan JE, Kruisbeek AM, Margulies DM, Shevach EM, Strober W, et al., editors. Current Protocols in Immunology. John Wiley & Sons; 2004. pp. 12.11.1–12.11.15.
    1. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol. 2005;79:10108–10125.
    1. Dubey S, Clair J, Fu TM, Guan L, Long R, et al. Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay. J Acquir Immune Defic Syndr. 2007;45:20–27.
    1. Li F, Malhotra U, Gilbert PB, Hawkins NR, Duerr AC, et al. Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine. 2006;24:6893–6904.
    1. Moodie Z, Huang Y, Gu L, Hural J, Self SG. Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials. J Immunol Methods. 2006;315:121–132.
    1. Horton H, Thomas EP, Stucky JA, Frank I, Moodie Z, et al. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods. 2007;323:39–54.
    1. Shulman N, Bellew M, Snelling G, Carter D, Huang Y, et al. Development of an automated analysis system for data from flow cytometric intracellular cytokine staining assays from clinical vaccine trials. Cytometry A. 2008;73:847–856.
    1. NIAID. Questions and Answers: The HVTN 505 HIV Vaccine Regimen Study. 2010. Available: . Accessed 2010 Dec 23.
    1. Jaoko W, Karita E, Kayitenkore K, Omosa-Manyonyi G, Allen S, et al. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS One. 2010;5:e12873.
    1. Kibuuka H, Kimutai R, Maboko L, Sawe F, Schunk MS, et al. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172). J Infect Dis. 2010;201:600–607.
    1. Peiperl L, Morgan C, Moodie Z, Li H, Russell N, et al. Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054). PLoS One. 2010;5:e13579.
    1. Emini EA. Ongoing development and evaluation of a potential HIV-1 vaccine using a replication-defective adenoviral vector. 2003. Keystone Symposium on HIV vaccines. Banff, Canada.
    1. Emini EA. A potential HIV-1 vaccine using a replication-defective adenoviral vaccine vector. 2002. 9th Conference of Retroviruses and Opportunistic Infections. Seattle, WA.
    1. Bansal A, Jackson B, West K, Wang S, Lu S, et al. Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration. J Virol. 2008;82:6458–6469.
    1. Launay O, Durier C, Desaint C, Silbermann B, Jackson A, et al. Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial. PLoS One. 2007;2:e725.
    1. Graham BS, Koup RA, Roederer M, Bailer RT, Enama ME, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis. 2006;194:1650–1660.
    1. Morgan C, Peiperl L, McElrath JM, Moodie Z, De Rosa SC, et al. 2007. DNA prime followed by adenoviral vector boost elicits HIV-1 specific CD8+ T cell responses in healthy HIV-1 uninfected adults (HVTN 052 and 057) AIDS Vaccine 2007 Seattle, WA.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere